Compare Duolingo Inc (DUOL) vs Johnson & Johnson (JNJ) Price & Performance

Duolingo (DUOL) trades at $151.16, down 0.37% on the day, as the stock consolidates near recent highs. The company demonstrates strong fundamental momentum with Q2 2026 EPS of $0.66 beating expectations of $0.604, marking the third consecutive quarterly beat. Revenue growth remains robust at 29% year-over-year, supported by a 36% net income margin. Technical indicators show a bullish trend with the stock trading above key support levels, though RSI suggests potential near-term overbought conditions.

Duolingo's outlook remains positive with accelerating revenue growth and expanding profitability, though the stock trades at a premium valuation with a P/E of 17.87. Key risks include CEO share sales and competitive pressures in the edtech space. Analyst consensus leans cautious with 37.5% buy ratings versus 54.2% hold, suggesting potential for re-rating if growth momentum continues.

Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.

JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.